Clinical trial · Observational
Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms
Clinical and Hematologic Risk Factors of Right Ventricular Dysfunction and Pulmonary Hypertension in Myeloproliferative Neoplasms
NCT07834918CI-TRIAL-00126507not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
This cross-sectional study aims to determine the prevalence of pulmonary hypertension and right ventricular dysfunction in patients with myeloproliferative neoplasms and to identify associated clinical and hematologic factors.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloproliferative Neoplasm | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
| Pulmonary Hypertension | — | UNRESOLVED | — |
| Right Ventricular Dysfunction | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Single cohort: Patients with myeloproliferative neoplasms
- description
- Adult patients with myeloproliferative neoplasms who will undergo clinical, laboratory, and echocardiographic assessment for pulmonary hypertension and right ventricular dysfunction.
Primary outcomes (1)
- measure
- Prevalence of Pulmonary Hypertension in MPN Patients
- timeFrame
- Baseline
- description
- PASP measured by echocardiography using TR velocity. Pulmonary hypertension defined as PASP greater than 35 mmHg or TR velocity greater than 2.8 m/s. Prevalence will be calculated.
Secondary outcomes (4)
- measure
- Prevalence of right ventricular dysfunction
- timeFrame
- Baseline
- description
- Proportion of patients with right ventricular dysfunction defined by TAPSE \<17 mm, RV fractional area change \<35%, or tissue Doppler S' \<9.5 cm/s
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \- Age 18 years or older * Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, or primary myelofibrosis) * Stable clinical condition * Written informed consent Exclusion Criteria: * \- Significant left-sided valvular heart disease * Congenital heart disease * COPD or interstitial lung disease causing pulmonary hypertension * Poor echocardiographic window
References
Publications (0)
Data not yet available
No reference posted for this study.